Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in PICU (TIP-15-01)

Inclusion Criteria: * Continuous analgesic and sedative endovenous treatment for at least 5 days * Invasive or non-invasive mechanical ventilation * Clinical conditions that allow by clinical judgment the start of analgosedation weaning * Post-natal age ≥ 7 days and PMA beyond the 37 weeks * Written informed consent obtained Exclusion Criteria: * Hemodynamic instability * Cardiac bundle-branch block of 2 or 3 degree * Hypersensitivity to the alpha-agonists * Persistent fever of unknown origin or sensitivity to malignant hyperthermia * Use of alpha-agonist (clonidine or dexmedetomidine) in the last 30 days